Loan Market Heats up as Summer Winds Down

Kellerhals, Richard
September 2010
High Yield Report;9/6/2010, Vol. 21 Issue 36, p10
The article focuses on the impact of the plan of U.S. banks to launch five deals as of September 2010 on the loan market. A term loan B backing the merger between Valeant Pharmaceuticals and Biovail will be arranged by Goldman Sachs, which has also arranged a term loan A and a revolver. Meanwhile, a second-lien term loan backing the merger of Pierre Foods with Advanced Foods will be marketed by a bank group led by Credit Suisse. The acquisition of Fort Dearborn by KRG Capital will be backed by a credit facility marketed by a bank consortium.


Related Articles

  • Deal May Bring Close to Valeant Locally. Reed, Vita // Orange County Business Journal;6/28/2010, Vol. 33 Issue 26, p1 

    The article reports on the deal between drug maker Valeant Pharmaceuticals International Inc. of Orange County, California and Biovail Corp. of Canada. The deal entitles Biovail to acquire and run some of the assets of Aliso. Moreover, the county has lost one of its public companies that...

  • Loan Market Heats up as Summer Winds Down. R. K. // Bank Loan Report;9/6/2010, Vol. 25 Issue 34, p1 

    The article reports on the business condition of the loan market in the U.S. It mentions the plans of banks to launch five deals amounting to 4 billion dollars. It notes that on September 8, 2010 Goldman Sachs & Co. will start marketing a 2.27 billion dollars term loan B that is supporting the...

  • Pumping more fuel into dealmaking.  // Mergers & Acquisitions: The Dealermaker's Journal;May/Jun95, Vol. 29 Issue 6, p39 

    Reports on commercial banks' financing of merger and acquisitions deals in 1994. Increase in loans extended from 1993 levels; Share of cash payments in deals as compared to stock-for-stock; Lead of Chemical Banking in terms of participation in loans.

  • Don't Look To M&A To Be Savior For Your HY Investments in 2001. Conrad, Lee // Bank Loan Report;01/15/2001, Vol. 16 Issue 2, p12 

    Discusses the outlook for financing of mergers and acquisitions in 2001. Merger deals that are expected to be completed; Effect of the public equity market's decline on potential acquisitions; Sector that is most likely to see successful leveraged buyouts.

  • Valeant Says 'Eye' to Buyout Of Visudyne: $112M for QLT. Osborne, Randy // BioWorld Today;9/25/2012, Vol. 23 Issue 186, p1 

    The article reports on QLT Inc.'s sale of its wet, age-related macular degeneration therapy, Visudyne, to Valeant Pharmaceuticals International Inc. Under the terms, QLT collected from Valeant 112.5 million U.S. dollars in cash. QLT also could receive as much as 5 million U.S. dollars in...

  • Merz Pharma Tops Valeant Offer for Obagi Medical. COLLINS, ALLISON // Mergers & Acquisitions Report;4/8/2013, Vol. 26 Issue 14, p1 

    The article offers information on the proposal of the company Merz Pharma Group to acquire the skin products company Obagi Medical Products Inc. in a deal worth 383.5 million U.S. dollars. It mentions that Valeant Pharmaceuticals International Inc. also made a 360 million U.S. dollars bid...

  • Numbers Give New View on Allergan Takeover Attempt. REED, VITA // Orange County Business Journal;6/2/2014, Vol. 37 Issue 22, p1 

    The article reports on the takeover bid of Valeant Pharmaceuticals International Inc. to California-based pharmaceutical company Allergan Inc. Discussed is Valeant's cash-and-stock offer for Allergan as well as the increase in the cash portion of the deal. The view of specialty pharmaceutical...

  • Valeant mulls higher Salix bid. Investor's Business Daily // Investors Business Daily;3/16/2015, pA02 

    The article focuses on the move of Valeant Pharmaceuticals to consider a higher bid for Salix Pharmaceuticals despite the comment of Bill Ackman, an investor at Valeant, that the bid will not overpay. It says that Valeant raises its offer to above $160. It adds that Valeant has paid a share and...

  • VALEANT PHARMACEUTICALS INTERNATIONAL INC.  // MondayMorning;3/19/2012, Vol. 20 Issue 12, p1 

    The article focuses on Valeant Pharmaceuticals International Inc.'s deal of buying a generic aspirin from Gerot Lannach GmbH. Austrian generic drugmaker to expand its business in the Europe with a 90 per cent sale of the drugs in Russia. Valeant has not yet disclosed the price the company is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics